PDGFRB and cancer: The trial for Regorafenib (NCT02795156), an inhibitor for a spectrum of RTKs, is currently recruiting patients with advanced cancer including UC and others with genomic alterations of VEGF, PDGFR, DDR2, etc. The trial for Nilotinib (NCT02029001) is recruiting patients with malignant solid neoplasms with mutations, amplification, or translocation of ABL1, KIT, PDGFRA, DDR1, DDR2, etc.